Can Fite BioPharma : Financial results for the six months en

Can Fite BioPharma : Financial results for the six months ended June 30, 2023 and updates on its drug development programs and an unaudited interim condensed consolidated financial statements as of June 30, 2023. -Today at 09:30 am

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of...

Related Keywords

Washington , United States , Israel , Israeli , American , Motti Farbstein , Kiryat Matalon , Commission File Number , Securities Exchange , Fite Biopharma Ltd , Foreign Private Issuer , Securities Exchange Act , Registration Statements , Can Fite Biopharma , Financial Review , Extension Schema Document , Extension Calculation Linkbase Document , Extension Definition Linkbase Document , Extension Label Linkbase Document , Extension Presentation Linkbase Document , Page Interactive Data File , Executive Officer , Can Fite Biopharma Ltd , New Israeli Shekel , Certain Terms , American Depositary Shares , Markets ,